With unprecedented rates of medical innovation, many biopharma companies and academic institutions are struggling to bring their products to market fast enough to realize their value. 

 

NAYA Biosciences aims to address this challenge through an agile and synergistic platform, backed by access to capital and public markets & driven by experienced, entrepreneurial leadership. 

 

Our unique business model is based on a portfolio approach, optimizing the risk-return investment profile through steady, scalable, profitable revenues augmented by the partnering upside of disruptive clinical-stage therapeutics. 

 

Fueled by this value creation approach, we aim to continue our strategic acquisition of undervalued specialty assets, accelerate their clinical development and commercialization, and capitalize on their potential to transform patients’ lives. 
 

​